For research use only. Not for therapeutic Use.
Ocrelizumab(CAT: I040854) is a monoclonal antibody that targets CD20, a cell surface protein found on B cells. By binding to CD20, Ocrelizumab depletes B cells, which play a key role in the pathogenesis of autoimmune diseases. Its mechanism of action involves antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of B cells. Ocrelizumab is primarily used in Neurological Disease Research, particularly in the treatment of multiple sclerosis (MS). It has shown efficacy in reducing relapse rates and slowing disease progression in patients with relapsing forms of MS and primary progressive MS.
| CAS Number | 637334-45-3 |
| Purity | ≥95% |
